C-CZACCerevance
NETSseq, CNS therapeutics, cell type-specific therapies
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CZAC
C-CZACC-CZACNETSseq, CNS therapeutics, cell type-specific therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cerevance states that human brain data are more likely than mouse data to translate into clinical success for neurodegenerative and higher-circuitry diseases, that highly sensitive profiling of vulnerable and disease-relevant brain cell types can reveal selectively expressed or dysregulated protein targets, and that drugs aimed at those selective targets should produce more effective treatments with fewer on-target side effects.
SourceCerevance states that human brain data are more likely than mouse data to translate into clinical success for neurodegenerative and higher-circuitry diseases, that highly sensitive profiling is needed to find low-expression therapeutic targets in the mature brain, and that drugs aimed at proteins selectively expressed in vulnerable or disease-relevant brain cell types can produce more effective treatments with fewer on-target side effects.
SourceCerevance presented the view that better therapies for brain disorders will come from studying the human brain directly, at the level of specific cell types, rather than relying mainly on indirect models. Its stated stance centered on using human brain tissue to uncover disease-relevant molecular signals and translate those findings into new treatments for neurological and neurodegenerative diseases such as Parkinson's and Alzheimer's.
SourceCerevance states that brain-disease therapies should be discovered by profiling specific human brain cell types and selectively targeting proteins expressed in vulnerable or disease-driving circuits. The company argues that human brain data are more likely than mouse data to translate into clinical success for neurodegenerative and higher-circuitry diseases, that highly sensitive methods are needed to detect low-level but important targets in the mature brain, and that drugs aimed at selectively expressed targets can deliver better efficacy, slow progression or relieve symptoms, and cause fewer on-target side effects.
SourceNo company mission, belief statement, or scientific position from Cerevance is visible in the provided 2017-05-03 Wayback snapshot text; the visible content is only Wayback Machine and Archive-It header metadata, so no stated company beliefs can be extracted from this capture.
Source